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Background    Recent case reports have identified an association 
between long-term bisphosphonate treatment and stress fractures 
of the femoral shaft. The risk of such fractures in bisphosphonate 
users has not been determined.
Methods   We identified women over 55 years of age with the 
specific fracture pattern by searching the operation registry of the 
hospitals in 2 healthcare districts. Prevalence of bisphosphonate 
treatment was provided by a Swedish national registry covering 
all drugs delivered to all individuals since 2005. 
Results   The number of women on bisphosphonate treatment 
was 3,087. Of these, 5 had femoral stress fractures. They had been 
taking bisphosphonates for 3.5 to 8.5 years. The incidence den-
sity for a patient on bisphosphonate was 1/1,000 per year (95% 
CI: 0.3–2). In the remaining 88,869 women who were not taking 
bisphosphonates, there were 3 stress fractures. Thus, their risk 
(without correction for inhomogeneity in age distribution) was 46 
times less (95% CI: 11–200). 
Interpretation   These results are rough estimations based on a 
comparatively small material. Still, a treatment-associated inci-
dence density of 1/1,000 is acceptable, considering that bisphos-
phonate treatment is likely to reduce the incidence density of any 
fracture by 15/1,000 according to a large randomized trial (Black 
et al. 1996).

There are several case reports on transverse fractures of the 
femoral shaft in patients who are on bisphosphonate treat-
ment (Goh et al. 2007, Kwek et al. 2008a, Kwek et al. 2008b, 
Lenart  et  al.  2008,  Neviaser  et  al.  2008,  Sayed-Noor  and 
Sjoden 2008). These fractures show cortical thickening as a 
sign of a stress fracture. They are often preceded by local pain 
for some weeks before a sudden break with minimal trauma. 
Many cases are bilateral. 
Most of these patients have taken a bisphosphonate for sev-
eral years (Neviaser et al. 2008). However, there have been 
no reports on the incidence of these fractures in patients on 
bisphosphonates, so the size of the risk is unknown. 
Our 4 hospitals take care of all fractures within their catch-
ment  areas  (with  570,000  inhabitants  in  total,  420,000  of 
which are in the county of Östergötland). The Swedish health 
authorities have registry data on all drugs taken by every indi-
vidual  in  the  population. We  could  therefore  calculate  the 
annual incidence of femoral shaft stress fractures in patients 
taking bisphosphonates. 
Patients and methods
All femoral shaft fractures with the diagnosis codes S72.30 
and S72.20 (ICD10 clinical coding system) in women over 55 
years of age were collected by searching the operation registry 
database of the university hospitals in Lund and Linköping. 
The Linköping database also covers the other 2 hospitals in the 
county of Östergötland. These hospitals take care of all trauma 
in their catchment areas. The time period evaluated for Lund 
was from January 2007 to May 2008 and for Linkoping from 
January 2007 to October 2008. All preoperative radiographs 
were examined by JS to identify stress fractures. Suspected 
stress  fractures  were  then  confirmed  by  PA,  without  prior 
discussion. This identification was done without any knowl-
edge of drug treatment. The stress fracture pattern, described 
by Lenart et al. (2008) as “simple with thick cortices”, was 
defined as a transverse fracture of the femoral shaft with corti-
cal thickening (Figure). 
The Swedish National Board of Health and Welfare pro-
vided prevalence data for continuous treatment with bisphos-
phonate  drugs  with  the  ATC  codes  M05BA  and  M05BB 
(M05BA:  bisphosphonate  drugs;  M05BB:  combinations  of 
bisphosphonate drugs with calcium) in the catchment areas of 
the hospitals. This database covers all pharmaceutical dispens-
ing to every patient in Sweden, and was introduced in July 414  Acta Orthopaedica 2009; 80 (4): 413–415
2005. Continuous treatment was defined as the patient having 
purchased the drug at least once every year from the introduc-
tion of the registry until July 2008. Statistics Sweden, a cen-
tral government authority for official statistics, provided popu-
lation data for the districts of interest in the study. Because 
both the population size and the number of bisphosphonate 
prescriptions were relatively constant over the years, we have 
regarded the data as reasonable estimations for incidence den-
sities. 
The medication status of each patient with a femoral stress 
fracture was evaluated by direct telephone contact with the 
patient. When data were unclear, we contacted the health ser-




We identified 8 patients with stress fractures of the femoral 
shaft. 5 of them were on continous treatment with bisphos-
phonate drugs. All of these patients were over 75 years of age. 
Mean treatment duration was 5.8 (3.5–8.5) years. One patient, 
who also had rheumatoid arthritis, had bilateral fractures. 
Of the 3 patients with stress fractures but no bisphosphonate 
treatment, 2 of them probably had poor bone health. One of 
them suffered from low-energy bilateral femoral shaft fractures 
6 years apart. She also suffered a perioperative pertrochanteric 
fracture while being operated for her first shaft fracture, and 
had refractures twice at the end of an osteosynthesis plate. 
Another  patient  suffered  from  chronic  active  autoimmune 
hepatitis, which was treated with low-dose steroids and mer-
captopurine before the stress fracture. In the third untreated 
patient, no predisposing factors were found. In contrast to the 
bisphosphonate-treated  patients,  those  without  bisphospho-
nates were all less than 75 years old.
In 2007, the overall population of women older than 55 years 
in the area of interest was 91,956. Of these, 3,087 (3.4%) were 
on continous treatment with bisphosphonate drugs. In order to 
combine the catchment areas of Östergötland county and Lund 
University Hospital and the different time intervals for evalua-
tion, we calculated the annual incidence of femoral shaft stress 
fractures to be 2.4 fractures per year, 1.5 of which were asso-
ciated with bisphosphonate treatment. The overall incidence 
of stress fractures in patients on continuous bisphosphonate 
treatment (weighted for the different catchment areas) was 
1/1,000 per year (95% CI: 0.3–2) as compared to 0.02/1,000 
(95% CI: 0.004–0.1) for the untreated women. 
Because of the small numbers, it was not possible to cal-
culate  the  relative  risk  for  separate  age  groups,  although 
there appeared to be different age distributions for fractures 
in bisphosphonate users and those who were not on bisphos-
phonates. As a rough estimate, we therefore calculated the 
relative  risk  without  age  correction,  and  found  a  46-times 




Is  the  risk  of  bisphosphonate-associated  fractures  so  great 
that treatment should be stopped? Our data suggest that it is 
not. The annual number of hip fractures in women over 65 
in Sweden is roughly 11,000, and the total number of osteo-
porosis fractures is much higher. Because the total number 
of women over 65 is about 900,000, our data suggest that if 
this entire population was given bisphosphonates, this would 
cause 900 stress fractures. This is clearly less than the number 
of osteoporosis fractures that would be avoided (Black et al. 
1996). 
Our calculations have several sources of uncertainty. The 
reason that we present our results in spite of these uncertain-
ties is that there have been no previous incidence calculations 
available at all. We calculated the relative risk without correc-
tion for inhomogeneity in age distribution.
Typical stress fracture in one of the bisphosphonate-treated patients. 
Note the transverse fracture line on the lateral side and the cortical 
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tors—the incidence density of 2 fractures would be squared, 
which  would  make  a  bilateral  fracture  extremely  unlikely. 
The bilateral fractures therefore corroborate the suspicion that 
patients with bisphosphonate-associated stress fractures carry 
some other risk factor in addition to taking the drug. 
 
We thank Urban Rydholm, Lund University, for giving us lists of all femoral 
shaft fractures at Lund University Hospital and Andrejs Leimanis of the Swed-
ish National Board of Health and Welfare for providing us with prevalence 
data from the registry. The research was funded by the Swedish Research 
Council and by Östergötland County, Sweden.
Per Aspenberg owns shares in a company that has a patent on a method for 
coating  orthopedic  implants  with  bisphosphonates. Apart  from  that,  both 
authors declare that there are no further conflicts of interests.
Black D M, Cummings S R, Karpf D B, Cauley J A, Thompson D E, Nevitt 
M C, Bauer D C, Genant H K, Haskell W L, Marcus R, Ott S M, Torner J 
C, Quandt S A, Reiss T F and Ensrud K E. Randomised trial of effect of 
alendronate on risk of fracture in women with existing vertebral fractures. 
Fracture  Intervention  Trial  Research  Group.  Lancet  1996;  348(9041): 
1535-41.
Black D M, Schwartz A V, Ensrud K E, Cauley J A, Levis S, Quandt S A, Sat-
terfield S, Wallace R B, Bauer D C, Palermo L, Wehren L E, Lombardi A, 
Santora A C and Cummings S R. Effects of continuing or stopping alendro-
nate after 5 years of treatment: the Fracture Intervention Trial Long-term 
Extension (FLEX): a randomized trial. Jama 2006; 296(24): 2927-38.
Goh S K, Yang K Y, Koh J S, Wong M K, Chua S Y, Chua D T and Howe T S. 
Subtrochanteric insufficiency fractures in patients on alendronate therapy: 
a caution. J Bone Joint Surg Br 2007; 89(3): 349-53.
Kwek E B, Goh S K, Koh J S, Png M A and Howe T S. An emerging pattern 
of subtrochanteric stress fractures: a long-term complication of alendronate 
therapy? Injury 2008a; 39(2): 224-31.
Kwek E B, Koh J S and Howe T S. More on atypical fractures of the femoral 
diaphysis. N Engl J Med 2008b; 359(3): 316-7; author reply 317-8.
Lenart B A, Lorich D G and Lane J M. Atypical fractures of the femoral 
diaphysis in postmenopausal women taking alendronate. N Engl J Med 
2008; 358(12): 1304-6.
Neviaser A S, Lane J M, Lenart B A, Edobor-Osula F and Lorich D G. Low-
energy femoral shaft fractures associated with alendronate use. J Orthop 
Trauma 2008; 22(5): 346-50.
Sayed-Noor A S and Sjöden G O. Subtrochanteric displaced insufficiency 
fracture after long-term alendronate therapy--a case report. Acta Orthop 
2008; 79(4): 565-7.
 
In the future, calculations should be based on larger popula-
tions, and should include such corrections. Our present results 
should be regarded as a first attempt to define the problem.
All patients with a bisphosphonate-associated stress fracture 
in our material were over 75 years of age. This may reflect 
the increasing number of bisphosphonate prescriptions with 
age, but the numbers are too small for certain conclusions to 
be reached. On the other hand, Kwek et al. (2007) reported a 
mean age of 66 years for their 17 patients.
It has been suggested that bisphosphonate treatment should 
be  terminated  after  5  years  (Black  et  al.  2006). We  could 
only determine the number of patients within the catchment 
area who had bisphosphonate treatment for a period of 2–3 
years. The number of patients with 5 years of treatment may 
have been less. In that case, the true incidence density—with 
5 years of treatment—might be higher. Not all patients who 
regularly take out their prescriptions do take their medicine, 
although the fact that they actually bought their medicine sug-
gests a reasonable degree of compliance. Thus, the stress frac-
ture incidence after 5 years of correct treatment was probably 
higher than our finding of 1/1,000. 
Nevasier et al. (2008) looked at all low-energy femoral shaft 
fractures at their hospital and found that among bisphospho-
nate users, the stress fractures occurred after a substantially 
longer treatment than other types of fractures, indicating that 
the risk of stress fracture increases with treatment time. Only 1 
of their 18 stress fracture patients had taken a bisphosphonate 
for less than 4 years, and the average duration of treatment was 
7 years. We found an average duration of 6 years, and Kwek et 
al. (2008) 5 years. Taken together, these findings suggest that 
treatment should be stopped after 5 years. It is not certain that 
prolongation of treatment for more than 5 years reduces the 
risk of osteoporosis fracture any further (Black et al. 2006).
We had 2 patients with bilateral fractures, 1 of whom was 
not on bisphosphonates. Half of Kwek’s patients had bilateral 
fractures (Kwek et al. 2008a). The high incidence of bilater-
ality suggests that the patients with bisphosphonate-associ-
ated stress fractures are derived from a subpopulation of all 
bisphosphonate-treated patients: if all patients on bisphospho-
nate in our study had the same incidence density of stress frac-
ture (1/1,000)—and if it were independent of individual fac-